Status:
ACTIVE_NOT_RECRUITING
Intraoperative Radiation Therapy for Resectable Pancreatic Cancer
Lead Sponsor:
Yona Cho
Conditions:
Resectable Pancreatic Cancer
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
This phase II study is designed to investigate the efficacy of intraoperative radiotherapy after neoadjuvant chemotherapy in patients with resectable pancreatic cancer. The purpose of the study is to ...
Eligibility Criteria
Inclusion
- Histologically diagnosed with adenocarcinoma of the pancreas or clinically diagnosed with imaging examinations or tumor markers
- 20 years or older
- Performance status 0-2 based on Eastern Cooperative Oncology Group (ECOG)
- Patients with surgically resectable or borderline resectable and advanced pancreatic cancer that can be resected after neoadjuvant chemotherapy
- Patients who voluntarily decided to participate in this clinical study and signed a written informed consent
Exclusion
- History of previous abdominal irradiation.
- When the treatment area is not included in the appropriate radiation field according to the judgment of the radiation oncologist or Durgeon
- Distant metastasis
- Other systemic conditions that, under the judgment of the attending physician, would be difficult to undergo surgery or radiiotherapy
Key Trial Info
Start Date :
April 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05181488
Start Date
April 2 2020
End Date
April 1 2026
Last Update
April 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gangnam Severance Hospital
Seoul, South Korea